New research from Mass General Brigham suggests an everyday multivitamin might slow cellular aging, showing modest shifts in DNA-based aging markers over two years in older adults. The randomized trial reported small but measurable changes across several epigenetic clocks, sparking interest in whether an inexpensive pill could nudge the biology of aging in a healthier direction.
A large, randomized clinical trial followed nearly 1,000 generally healthy older adults, average age 70, and split them into four groups to test multivitamins and cocoa extract in various combinations. One group took a daily multivitamin-multimineral plus cocoa extract, another took cocoa with a placebo, a third took a multivitamin with placebo, and the last took only placebos. Blood samples collected at three points were analyzed for five epigenetic clocks, biomarkers that track age-related changes at the DNA level. The main finding was a slowdown in biological aging among those taking a daily multivitamin over the two-year period.
Across all five biomarkers, the multivitamin group showed signs of slower biological aging, with the measured effect averaging roughly four months less aging compared with placebo over the trial period. The benefit appeared strongest in participants whose biological age was already older than their chronological age, hinting at a potential for targeted benefit. Researchers reported the results in a peer-reviewed journal and framed them as a promising, accessible intervention worth deeper study. The practical implications for disease risk or longevity, however, remain unclear.
“Aging at the cellular level can be marked by DNA methylation, where in some cells it decreases and in some it increases,” Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital. “This is also described as epigenetic changes – or DNA expression.” Those shifts in methylation are what epigenetic clocks measure, and small moves on those clocks are being interpreted as slower biological wear and tear. Still, a change on a molecular clock is not the same as a demonstrated reduction in heart attacks, dementia, or cancer.
The study team emphasized caution about overinterpreting the size of the effect, noting that the aging slowdown was modest and that the trial was not designed to show changes in clinical outcomes. The participant pool skewed older and was largely of European ancestry, so the findings may not apply broadly across ages or ethnic groups. The trial also left open the key question of which ingredients in the multivitamin, if any single ones, drove the effect. Until those mechanisms are clear, recommendations should remain measured.
“There is a lot of interest today in identifying ways to not just live longer, but to live better,” said senior author Howard Sesso, associate director of the Division of Preventive Medicine in the Mass General Brigham Department of Medicine. “It was exciting to see the benefits of a multivitamin linked with markers of biological aging. This study opens the door to learning more about accessible, safe interventions that contribute to healthier, higher-quality aging.”
Outside experts welcomed the rigor of a randomized design but urged further work to pin down cause and effect. “There are so many possibilities, from biotin to calcium to zinc to vitamin B, C or D … to niacin and to metals like magnesium and copper,” he told Fox News Digital. “I am personally a believer in riboflavin, thiamine and vitamin D, but further research is needed to parse this out and determine a cause-effect relationship.” That honest uncertainty leaves room for follow-up trials that isolate specific nutrients or test different doses.
The investigators plan additional studies to see whether the multivitamin’s effect persists beyond the trial window and whether changes in epigenetic clocks translate into fewer age-related illnesses. Future work will also explore cognitive outcomes and potential links with cancer risk, attempting to connect molecular signals to real-world health. The research was funded by a national health agency and adds to a small but growing body of randomized evidence about common supplements and aging biology.
